No Data
No Data
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $65
Corbus Pharmaceuticals (CRBP) Receives a Buy From RBC Capital
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $60
Corbus Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
No Data
No Data